Delivery Order SPE2DB20D2002-SPE2DB22FL45M
Award Date 6/8/22
Potential Completion Date 6/9/22
Potential Value $79K
Federal Agency
Awardee
Ultimate Awardee
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This federal contract award, valued at $28,154.40, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine. The contract has a firm fixed price pricing type and an ultimate completion date of September 19, 2022. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that plays a critical role in...
- This federal contract award, valued at $153,284.00, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine. This is a firm-fixed-price delivery order contract with a completion date of May 11, 2023. The award was made without any set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a major pharmaceutical...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine. The contract has a ceiling value of $67,356.00 and an ultimate completion date of October 21, 2021. This is a delivery order contract, with a firm fixed price pricing type. Amerisourcebergen Drug Corp is a subsidiary of the parent company...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $157,728.00 Firm Fixed Price Delivery Order is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine. The contract has an ultimate completion date of August 28, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $55,741.32 firm fixed-price delivery order is for the procurement of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine. The contract has an ultimate completion date of August 14, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $31,545.60 firm fixed-price delivery order is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine, with a completion date of July 23, 2024. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, which...
- This federal contract award, valued at $91,324.00, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor, Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The award is for the delivery of HEPLISAV-B, a 20 mcg/0.5 ml hepatitis B vaccine, to support military and federal healthcare programs. The contract is a firm-fixed-price delivery order with a completion date of November 30, 2021. This award is not associated with a set-aside designation,...
- This federal contract award, valued at $1,182.96, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine, with an ultimate completion date of October 17, 2024. The contract is a Delivery Order with a Firm Fixed Price pricing type. This award is not associated with a set-aside designation, indicating open...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $18,977.16 Firm Fixed Price delivery order covers the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine product. The award has an ultimate completion date of August 28, 2024. There was no set-aside designation, indicating open competition. AmerisourceBergen holds a significant $999,999,999...
- This federal contract award, valued at $23,574.60, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML vaccine, with a completion date of August 4, 2021. No set-aside designation was used for this award. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which specializes in pharmaceutical...